Loading...
Please wait, while we are loading the content...
Similar Documents
How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation
| Content Provider | Scilit |
|---|---|
| Author | Spyridonidis, Alexandros |
| Copyright Year | 2020 |
| Description | Although allogeneic hematopoietic cell transplantation (allo-HCT) is currently the standard curative treatment of acute leukemia, relapse remains unacceptably high. Measurable (minimal) residual disease (MRD) after allo-HCT may be used as a predictor of impending relapse and should be part of routine follow-up for transplanted patients. Patients with MRD may respond to therapies aiming to unleash or enhance the graft-versus-leukemia effect. However, evidence-based recommendations on how to best implement MRD testing and MRD-directed therapy after allo-HCT are lacking. Here, I describe our institutional approach to MRD monitoring for preemptive MRD-triggered intervention, using patient scenarios to illustrate the discussion. |
| Related Links | https://ashpublications.org/blood/article-pdf/doi/10.1182/blood.2019003566/1558017/blood.2019003566.pdf |
| Ending Page | 1649 |
| Page Count | 11 |
| Starting Page | 1639 |
| DOI | 10.1182/blood.2019003566 |
| Journal | Blood |
| Issue Number | 19 |
| Volume Number | 135 |
| Language | English |
| Publisher | American Society of Hematology |
| Publisher Date | 2020-05-07 |
| Access Restriction | Open |
| Subject Keyword | Hematology Treatment Hematopoietic Transplantation Allogeneic Leukemia Relapse Residual Hct Mrd Journal: Blood (Vol- 131, Issue- 19) |
| Content Type | Text |
| Resource Type | Article |